Rheumatoid arthritis

被引：53

作者：

Diaz-Gonzalez, Federico ^{[1
,2
,3
]}

Hernandez-Hernandeza, Maria V. ^{[1
]}

机构：

[1] Hosp Univ Canarias, Serv Reumatol, Tenerife, Spain

[2] Univ La Laguna, Dept Med Interna Dermatol & Psiquiatria, San Cristobal De La Lagun, Tenerife, Spain

[3] Univ La Laguna, Inst Univ Tecnol Biomed ITB, San Cristobal De La Lagun, Tenerife, Spain

来源：

MEDICINA CLINICA | 2023年 / 161卷 / 12期

关键词：

Rheumatoid arthritis; Etiopathogenesis; Treatment; Treat to target strategy; Disease activity; CITRULLINATED PEPTIDE ANTIBODIES; DISEASE-ACTIVITY SCORE; C-REACTIVE PROTEIN; CLASSIFICATION CRITERIA; CLINICAL-PRACTICE; AMERICAN-COLLEGE; DOUBLE-BLIND; ANTI-TNF; METHOTREXATE; MORTALITY;

D O I：

10.1016/j.medcli.2023.07.014

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Rheumatoid arthritis (RA) is a chronic inflammatory multisystemic disease of unknown etiology and autoimmune nature that predominantly affects peripheral joints in a symmetrical fashion. Although much progress has been made in understanding the pathophysiology of RA, its etiology remains unknown. Tumor necrosis factor (TNF)-a and interleukin (IL)-6 play the important roles in the pathogenesis and maintenance of inflammation in RA. The presence of anti-citrullinated peptide antibodies aids in the diagnosis in patients with undifferentiated polyarthritis and is associated with a more aggressive RA. The natural history of RA causes joint deformity and disability, as well as reduced life expectancy, both due to increased cardiovascular risk, pulmonary involvement, infections, iatrogenesis or tumors. Early diagnosis and the use of targeted drugs to induce early remission have improved the RA prognosis. (c) 2023 Elsevier Espana, S.L.U. All rights reserved.

引用

页码：533 / 542

页数：10

共 60 条

[1] Disease-modifying antirheumatic drug-free sustained remission in rheumatoid arthritis: an increasingly achievable outcome with subsidence of disease symptoms [J].

Ajeganova, S. ;

van Steenbergen, H. W. ;

van Nies, J. A. B. ;

Burgers, L. E. ;

Huizinga, T. W. J. ;

van der Helm-van Mil, A. H. M. .

ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 (05) :867-873

[2]

Alemao E, 2020, CLIN EXP RHEUMATOL, V38, P455

[3]

Aletaha D, 2005, CLIN EXP RHEUMATOL, V23, pS100

[4]

Aletaha D, 2010, ANN RHEUM DIS, V69, P1580, DOI [10.1136/ard.2010.138461, 10.1002/art.27584]

[5] The role of female hormonal factors in the development of rheumatoid arthritis [J].

Alpizar-Rodriguez, Deshire ;

Pluchino, Nicola ;

Canny, Geraldine ;

Gabay, Cem ;

Finckh, Axel .

RHEUMATOLOGY, 2017, 56 (08) :1254-1263

[6] Window of opportunity in rheumatoid arthritis - definitions and supporting evidence: from old to new perspectives [J].

Burgers, Leonie E. ;

Raza, Karim ;

van der Helm-van Mil, Annette H. .

RMD OPEN, 2019, 5 (01) :V

[7] Controversies in rheumatology: maintenance therapy with low-dose glucocorticoids in rheumatoid arthritis [J].

Buttgereit, Frank ;

Kvien, Tore K. .

RHEUMATOLOGY, 2022, 62 (01) :35-41

[8] Future use of musculoskeletal ultrasonography and magnetic resonance imaging in rheumatoid arthritis [J].

Carstensen, Stine Maya Dreier ;

Terslev, Lene ;

Jensen, Mogens Pfeiffer ;

ostergaard, Mikkel .

CURRENT OPINION IN RHEUMATOLOGY, 2020, 32 (03) :264-272

[9] Methotrexate and mortality in patients with rheumatoid arthritis:: a prospective study [J].

Choi, HK ;

Hernán, MA ;

Seeger, JD ;

Robins, JM ;

Wolfe, F .

LANCET, 2002, 359 (9313) :1173-1177

[10] NLRC4-mediated activation of CD1c+DC contributes to perpetuation of synovitis in rheumatoid arthritis [J].

Delgado-Arevalo, Cristina ;

Calvet-Mirabent, Marta ;

Triguero-Martinez, Ana ;

de Luis, Enrique Vazquez ;

Benguria-Filippini, Alberto ;

Largo, Raquel ;

Calzada-Fraile, Diego ;

Popova, Olga ;

Sanchez-Cerrillo, Ildefonso ;

Tsukalov, Ilya ;

Moreno-Vellisca, Roberto ;

de la Fuente, Hortensia ;

Herrero-Beaumont, Gabriel ;

Ramiro, Almudena ;

Sanchez-Madrid, Francisco ;

Castaneda, Santos ;

Dopazo, Ana ;

alvaro, Isidoro Gonzalez ;

Martin-Gayo, Enrique .

JCI INSIGHT, 2022, 7 (22)

← 1 2 3 4 5 6 →